Different glucose metabolism behavior relating to histotypes in synchronous breast cancers evaluated by [18F]FDG PET-CT
Abstract
Glucose metabolism is increased in most aggressive tumors and it is commonly evaluated by positron emission tomography-computed tomography (PET-CT) with 18F-fluorodeoxyglucose ([18F]FDG), measuring the Maximum Standardized Uptake Value (SUVmax) for the assessment. Particularly, it is known that breast cancer expresses different glucose metabolism inrelation to estrogen receptor (ER), progesterone receptor (PR), Ki67 score, tumor grading, tumor size, and Human Epidermal Growth Factor Receptor 2 (HER2). We present an interesting case of a woman with two different, synchronous breast cancers characterized by different glucose metabolism, according to literature knowledge.
Keywords: Breast cancer[18F]FDGPEThistotypeglucose metabolism
References
- Cerci SM, Bozkurt KK, Eroglu HE, et al. Evaluation of the association between HIF-1α and HER-2 expression, hormone receptor status, Ki-67 expression, histology and tumor FDG uptake in breast cancer. Oncol Lett. 2016; 12(5): 3889–3895.
- Qu YH, Long N, Ran C, et al. The correlation of F-FDG PET/CT metabolic parameters, clinicopathological factors, and prognosis in breast cancer. Clin Transl Oncol. 2021; 23(3): 620–627.
- Albano D, Bertoli M, Morassi ML, et al. Incidental 18F-FDG PET/CT bilateral breast uptake due to carcinoma. Nucl Med Rev Cent East Eur. 2016; 19(B): 14–16.
